This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Purdue Pharma Increases Adoption Of Medidata Clinical Cloud To Strengthen R&D Operations

Medidata Solutions (NASDAQ: MDSO) signed Purdue Pharma L.P. to a multi-year enterprise agreement that significantly broadens its already wide use of Medidata’s cloud-based solutions, to further improve clinical trial operational efficiencies, resource savings and decision making. Purdue is also renewing the Medidata applications it currently uses across its portfolio of innovative treatments for pain, sleep and gastrointestinal disorders.

Relying on a range of Medidata products for all major studies since 2010, including study and protocol design tool Medidata Designer ® and electronic data capture and management system Medidata Rave ®, Purdue recently adopted Medidata’s clinical trial management system (CTMS) and is now adding clinical business analytics with Medidata Insights™, including its innovative site quality management module, as well as support for risk-based monitoring with Rave Targeted SDV and additional modules of the site budgeting and financial management tool Medidata Grants Manager ®.

For the past three years, Purdue’s management has witnessed significant productivity improvements in its clinical trial operations with Medidata’s cloud-based solutions. Before expanding its use of the Medidata platform, Purdue conducted a complete ROI analysis to secure buy-in from executive management on the implementation.

  • “After seeing the results we were able to achieve with Medidata’s Clinical Cloud, we have enthusiastically embraced a number of new capabilities,” said Charles Willmer, senior director of clinical systems, Purdue. “Expanding our use of Medidata’s platform will enable us to reduce cost, complexity and time in site negotiation and monitoring, track CRO activities more efficiently, and improve visibility into study performance.”

Using Medidata Designer, Purdue has streamlined the design process and increased downstream visibility into the impacts of design decisions, leading to improvements in quality and timelines. Purdue’s use of Medidata Rave for data management and capture across its global trials is driving fast trial start-up times: study build timelines have decreased to less than eight weeks. The company is also leveraging Rave’s standards-based infrastructure to easily import data from other clinical technologies for additional study efficiencies.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs